Immunotherapy Does adjuvant ipilimumab have little adverse effect on quality of life?
Abstract
Adjuvant ipilimumab is associated with an 11% improvement in 5-year overall survival in patients with high-risk melanoma, but at the cost of considerable toxicity, with half of patients discontinuing treatment owing to adverse events. An analysis of quality-of-life (QoL) outcomes, however, showed little impact of adverse effects of this treatment on QoL, which is puzzling.
| Authors | Lorigan, Paul; Green, Adele C. |
|---|---|
| Journal | Nature Reviews Clinical Oncology |
| Pages | 395-396 |
| Volume | 14 |
| Date | 1/07/2017 |
| Grant ID | |
| Funding Body | Amgen |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038/nrclinonc.2017.60 |